Although GluR1 o and GluR3 o are homologous at the amino acid level, GluR3 o desensitizes approximately threefold faster than GluR1 o . By creating chimeras of GluR1 o and GluR3 o and point amino acid exchanges in their S2 regions, two residues were identified to be critical for GluR1 o desensitization: Y716 and the R/G RNA-edited site, R757. With creation of the double-point mutant (Y716F, R757G)GluR1 o , complete exchange of the desensitization rate of GluR1 o to that of GluR3 o was obtained. In addition, both the potency and affinity of the subtype-selective agonist bromohomoibotenic acid were exchanged by the Y716F mutation. A model is proposed of the AMPA receptor binding site whereby a hydrogen-bonding matrix of water molecules plays an important role in determining both ligand affinity and receptor desensitization properties. Residues Y716 in GluR1 and F728 in GluR3 differentially interact with this matrix to affect the binding affinity of some ligands, providing the possibility of developing subtype-selective compounds.
L-glutamate, the major excitatory neurotransmitter in the brain, activates three distinct types of ionotropic glutamate receptors (iGluR): NMDA receptors, AMPA receptors (AMPARs), and kainate (KA) receptors (for review, see Hollmann and Heinemann, 1994; Dingledine et al., 1999) . These receptor channels consist of a heteromeric complex composed of four or five subunits (Ferrer-Montiel and Montal, 1996; Mano and Teichberg, 1998; Rosenmund et al., 1998) . Four different subunits (GluR1-4) can contribute to the formation of AMPARs and are capable of forming functional homomeric and heteromeric channels (Brose et al., 1994) . GluR1-4 can exist in two alternate splice versions, termed flip and flop (Sommer et al., 1990) , which show differences in their desensitization properties Koike et al., 2000) and their sensitivity to blockers of desensitization, such as cyclothiazide (Partin et al., 1994) . In addition, in GluR2, GluR3, and GluR4, intronic elements determine a codon switch in the primary transcripts at a position termed the R/G site that immediately precedes the flip/flop region (Lomeli et al., 1994) . The R/G site also affects receptor desensitization properties as well as recovery from desensitization.
Native and cloned AMPARs desensitize rapidly and almost completely in response to glutamate application, on a millisecond time scale (Mayer and Westbrook, 1987; Stern-Bach et al., 1998; Dingledine et al., 1999) . Excessive activation of iGluRs, for example by blocking their desensitization, may mediate neuronal excitotoxic death (Jensen et al., 1998 (Jensen et al., , 1999 . Consequently, iGluRs are thought to play a role in several neurological disorders and neurodegenerative diseases (Bittigau and Ikonomidou, 1997) . However, although there is substantial knowledge relating to iGluR desensitization at the cellular level, relatively little is known about the molecular mechanism of desensitization. In contrast, the characterization of the agonist binding domain of iGluRs has been greatly advanced by x-ray crystal structure data of soluble GluR2 binding domain constructs consisting of segments S1 and S2 joined together by a polypeptide linker (Armstrong et al., 1998; Armstrong and Gouaux, 2000) . S1 is located N-terminal to transmembrane domain I (TMD I), whereas S2 is situated between TMD III and TMD IV and contains the flip/flop and R/G sites. Agonist binding to AMPARs is thought to involve an interaction of S1 with S2 that yields a closed configuration, which has been suggested to be related to both efficacy and desensitization (Paas, 1998; Armstrong and Gouaux, 2000; Krupp and Westbrook, 2000) .
In the present study, AMPAR amino acid residues involved in both ligand binding and channel gating were investigated by creating receptor chimeras and point exchanges between two homologous AMPAR subunits, GluR1 o and GluR3 o . Because GluR3 o has a faster desensitization rate constant than GluR1 o , it was possible to investigate the molecular reasons for this difference. In addition, although the homology in the S1 and S2 regions between these subunits is 81 and 92%, respectively, they are not identical. Our recent discovery (Coquelle et al., 2000) of an AMPAR subtype-selective agonist, ( S)-4-bromohomoibotenic acid [( S)-BrHIBO] , made it possible to investigate differences in the binding sites of GluR1 o versus GluR3 o responsible for determining this selectivity.
MATERIALS AND METHODS
Mutagenesis. For preparation of high-expression cRNA transcripts, GluR1 o and GluR3 o (provided by Dr. S. F. Heinemann, The Salk Institute, La Jolla, CA) were each inserted into the pGEM H E vector (Liman et al., 1992) at the (5Ј)-BamHI and (3Ј)-XbaI sites of the multiple cloning site. All of the 5Ј and 3Ј untranslated sequence had been removed from these clones. GluR4c o in pBluescript SK(Ϫ) vector (kindly supplied by Dr. A. Buonanno, National Institutes of Health, Bethesda, MD) was digested with XhoI, treated with K lenow enzyme to produce blunt ends, and subsequently digested with BamHI. The GluR4c o insert was then subcloned into the (5Ј)-BamHI and (3Ј)-XbaI (blunt-ended with K lenow enzyme) sites of pGEM H E vector, leaving a 58 bp 5Ј-and Ϸ430 bp 3Ј-untranslated sequence. Mutagenesis was performed with the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) using the GluR1 o , GluR3 o , or GluR4c o pGEM H E cDNA as a template. Mutagenic oligonucleotides were obtained from DNA Technology A /S (Aarhus, Denmark) and also contained silent restriction sites for screening of mutant colonies. Mutated regions were cassetted back into the corresponding template cDNA and then sequenced-verified using the BigDye Terminator C ycle Sequencing K it and an Applied Biosystems Prism 310 Sequencer (Perkin-Elmer, Foster C ity, CA). cDNAs were grown in X L1 Blues bacteria (Stratagene) and prepared using column purification (Qiagen, Chatsworth, CA). cRNA was synthesized from these cDNAs using the mMessage mMachine T7 mRNA-capping transcription kit (Ambion, Austin, TX).
Creation of chimeric receptors. Chimeric GluR1 o -GluR3 o receptors were created using naturally occurring restriction enzyme sites in the wild-type receptor cDNAs (Fig. 1) . Construction of chimeras 1 and 2 has been described previously (Banke et al., 1997) ; these chimeras were formerly named NG1-CG3 and NG3-CG1, respectively.
Recombinant baculovirus construction. The baculovirus-Sf9 cell system was used to express recombinant AM PAR complexes used for radioligand binding assays. All manipulations of virus and insect cells, including maintenance of cell culture, transfection, plaque purification, amplification, and expression of receptor, were according to standard protocols in the Guide to Baculovirus E xpression Vector Systems and Insect Cell Culture Techniques (Life Technologies, Paisley, UK) and Baculovirus E xpression Vector System: Procedures and Methods Manual, Second Edition (PharMingen, San Diego, CA) . The creation and expression of recombinant GluR1 o and GluR3 o baculoviruses and Sf9 cell culture have been described previously (Nielsen et al., 1998) . Baculoviruses of the mutants (Y716F, R757G)GluR1 o , (Y716F)GluR1 o , (F728Y, G769R)GluR3 o , and (F728Y)GluR3 o were made in the same manner by subcloning these mutants from the pGEM H E vector into a baculovirus transfer vector and using the PharMingen BaculoGold transfection kit.
Radioligand binding. The affinities of compounds at wild-type and mutant receptors were determined from competition experiments with (R,S)- [5-methyl-3 H]AM PA (40.87 C i /mmol; N EN, Boston, M A) as described previously (Nielsen et al., 1998; Coquelle et al., 2000) . Competition data were fit to a logistic equation (Eq. 1) to determine the Hill coefficient (n H ) or to Equation 2 for calculation of the drug affinity (K i ):
where K d equals radioligand dissociation constant, K i equals inhibitor dissociation constant, L t equals total radioligand concentration, TB max equals total radioligand bound at zero competitor concentration, n H equals Hill coefficient, NSB equals nonspecific binding, and [I] equals total competitive inhibitor concentration. Ooc yte preparation. Mature female Xenopus laevis (African Reptile Park, Tokai, South Africa) were anesthetized using 0.1% ethyl 3-aminobenzoate, and ovaries were surgically removed. The ovarian tissue was dissected and treated with 2 mg /ml collagenase in C a 2ϩ -free Barth's medium for 2 hr at room temperature and subsequently defolliculated using fine forceps. On the second day, oocytes were injected with 50 -100 nl of ϳ1 g/l cRNA and incubated in Barth's medium (in mM): 88 NaC l, 1 KC l, 0.33 C a(NO 3 ) 2 , 0.41 C aC l 2 , 0.82 MgSO 4 , 2.4 NaHC O 3 , and 10 H EPES, pH 7.4, with gentamicin (0.10 mg /ml) at 17°C. Oocytes were used for recordings from 6 to 10 d after injection.
Two-electrode voltage clamp. The oocytes were voltage-clamped by using a two-electrode voltage clamp (Dagan Corporation, Minneapolis, M N) having a virtual ground, with both microelectrodes filled with 3 M KC l. Recordings were made while the oocytes were continuously superf used with frog Ringer's solution (in mM): 115 NaC l, 2 KC l, 1.8 C aC l 2 , and 5 H EPES, pH 7.0. Drugs were dissolved in Ringer's solution and were added by bath application. All recordings were made at room temperature at a holding potential (V h ) of Ϫ80 mV. In our hands, oocyte The corresponding restriction enzyme sites in the cDNA used to create these constructs are also indicated. The amino acid length of each protein is given in square brackets. Note that chimeras 1 and 2 were previously named NG1-CG3 and NG3-CG1, respectively (Banke et al., 1997) , but have been renamed here for simplicity. TMD I through TMD IV are indicated as boxes; N, N terminus; C, C terminus. This figure is not drawn to scale. calcium-activated chloride channels have never been observed to interfere with the expressed AM PAR currents.
Agonist concentration-response curves were constructed by measuring the maximal current induced by increasing concentrations of agonist. Data from individual oocytes were fit to a logistic equation:
n H], where I is the response observed at a given agonist concentration. The parameters I max (maximal current observed at infinite agonist concentration), n H (Hill coefficient), and the EC 50 were determined by an iterative least squares fitting routine.
Patch-clamp recordings. Injected oocytes were prescreened with a twoelectrode voltage clamp; those having a response Ͼ200 nA (V h ϭ Ϫ80 mV) to 300 M K A were selected for f urther investigation. The vitelline membrane was removed by placing the oocyte in a 35 mm dish containing a hyperosmotic medium (in mM): 200 K ϩ -aspartate, 20 KC l, 1 MgC l 2 , 5 EGTA-KOH, and 10 H EPES-KOH, pH 7.4. After 10 -15 min in this solution, the vitelline membrane was removed with a pair of fine forceps. Outside-out patches from oocytes were prepared with thin-walled glass capillaries (World Precision Instruments, Sarasota, FL) filled with (in mM): 100 KC l, 10 EGTA, and 10 H EPES, pH 7.0. Pipettes had a resistance of 3-5 M⍀. The external solution was frog Ringer's. Fast application of agonists to outside-out membrane patches was made using a double-barreled theta-glass tube (outer diameter, 2.0 mm; wall thickness, 0.3 mm; septum thickness, 0.12 mm; Hilgenberg, Malsfeld, Germany). Frog Ringer's solution flowed continuously through one barrel, while the other barrel contained either 10 mM L-glutamate or 1 mM (R,S)-BrHI BO. The theta-glass tube was stepped using a piezo-electric element (Burleigh Instruments, Fishers, N Y) . By measuring the change in junction current between two different buffer solutions, the 10 -90% rise time was determined to be Ͻ100 sec. Rate constants ( values) were determined by fitting the average macroscopic responses to the following rate equation:
Ϫt / ϩ I ss , where A t is the current amplitude at time (t), A o is the maximum current amplitude, e is the base of the natural logarithm, I ss is the steady-state current, and is the rate constant. Currents were recorded with an RK-400 amplifier (Bio-L ogic Science Instruments, C laix, France), filtered at 2 kHz, and digitized with a sampling rate of 20 kHz; data were stored on-line onto a personal computer hard disk drive.
Sequence and data anal yses sof tware. Nucleotide and protein alignments and sequence comparisons were performed using PC gene version 6.60 (IntelliGenetics Inc., Mountain View, CA). The GluR1 o , GluR3 o , and GluR4c o proteins are numbered here beginning from the initiation methionine. The numbering for GluR2 is as given in Armstrong et al. (1998) . Unless otherwise stated, one-way ANOVA (followed by the Bonferroni t test, if required) or Student's t test was used for comparison of the parameters of the receptors using SigmaStat for Windows version 2.0 (SPSS Science, Chicago, IL) or GraphPad (San Diego, CA) Instat version 2.01. Values were considered statistically significantly different if p values were Ͻ0.05. Electrophysiological data were analyzed as described above using N PM (written by Dr. Steve Traynelis, Emory University, Atlanta, GA), VC lamp version 6.0 (C ambridge Electronic Design, C ambridge, UK), and Origin version 5.0 (Microcal Software, Northampton, M A); binding data were analyzed using Grafit version 3.00 (Erithacus Software L td., Horley, UK).
Molecular modeling. The amino acid sequences of GluR1-4 (flop versions) were aligned with the GluR2-S1S2I construct described by Armstrong et al. (1998) using Macaw software version 2.0.5 (http:// w w w.ncbi.nlm.nih.gov) (Schuler et al., 1991; Lawrence et al., 1993) . Models of the binding sites of GluR1-4 were built from GluR2-S1S2J complexed with various ligands (Armstrong et al., 2000) by interchanging homologous amino acids, in particular Y702 (GluR2) for phenylalanine in GluR3 and GluR4. This was justified on the basis of previous models of GluR1-4 homology built from GluR2-S1S2I using Swiss-Model via the E xpert Protein Analysis System (E xPASy) Molecular Biology Server (Swiss Institute of Bioinformatics, Geneva, Switzerland; http:// w w w.expasy.ch), which showed very little deviation of backbone and side chains around the binding site.
Based on the crystal structures of GluR2-S1S2J complexed with L-glutamate and ( S)-AM PA (Armstrong et al., 2000) , models were constructed of these ligands as well as for ( S)-BrHI BO bound to GluR1 and GluR3. A reasonable binding conformation for the tri-ionized form of ( S)-BrHI BO was found by a Monte C arlo search of the conformational space according to the MM FF94 forcefield in MacroModel version 6.5 (Mohamadi et al., 1990) including the GB/SA solvation model. The chosen local minimum energy conformation lay 0.05 kcal /mol above the global minimum. The binding positions of ( S)-BrHI BO were estimated by overlaying the formally charged atoms of ( S)-BrHI BO on ( S)-AMPA. The two ␣-amino acid portions were matched directly, but the isoxazole ring of ( S)-BrHI BO was inverted around the carboxylate bioisostere, matching the ring N with O1 and vice versa, as suggested previously (Christensen et al., 1992; Greenwood et al., 1998) .
C alculations were performed to confirm the preferred sites for water molecules within the ligand-binding cavities of the agonist-bound state of the GluR1 and GluR3 homology models using the program GRI D, version 18 (Goodford, 1985) . The proton positions and hydrogenbonding networks were established by a combination of inspection, energy minimization, and Monte C arlo methods to resolve ambiguities as follows: all waters and side-chain hydroxyls within 8.5 Å of the ligand were rotated randomly to give thousands of initial structures. The positions of the protons were then optimized, including all atoms within a 12.5 Å radius, again using the MM FF94 forcefield (Mohamadi et al., 1990) . (For additional details concerning our homology models, interested readers may contact Prof. Tommy Liljefors at the following e-mail address: tl@df h.dk.)
Finally, simplified models of both HI BO-type and AM PA-type binding relative to the nonconserved Y716(GluR1)/ F728(GluR3) residue were constructed, consisting of a benzene or phenol ring representing this residue (TYR or PH E), a deprotonated 3-hydroxy-4,5-dimethylisoxazol anion representing either AMPA (I) or 4-methylhomoibotenic acid (MeHI BO), and two interposing water molecules corresponding to W1 and W3. Fixing as few internal geometric coordinates as possible to retain approximate relative orientations, the four models (I-TYR, I-PH E, II-TYR, and II-PH E) were submitted to quantum mechanical energy minimizations using ab initio B3LYP density f unctional theory with the 6 -31ϩG(d) basis set in Gaussian 98 version A.7 (Gaussian Inc., Pittsburgh, PA). 
RESULTS

Desensitization of wild-type and chimeric AMPARs
The gating properties of the wild-type, homomeric AMPAR subunits were characterized in X. laevis oocytes injected with wild-type GluR1 o or GluR3 o cRNA. Because the observed desensitization rate constant () can be dependent on agonist concentration, a high concentration of L-glutamate was used such that was independent of agonist concentration (Koike et al., 2000) . Responses of GluR1 o and GluR3 o to fast application (Ͻ100 sec) of either 10 mM L-glutamate (Fig. 2 A) or 1 mM BrHIBO (Fig. 2 B) were examined. GluR1 o exhibited a slower desensitization rate compared with GluR3 o for both agonists, whereas no difference was seen between these agonists. However, the 10 -90% rise time for 1 mM (R,S)-BrHIBO at GluR1 o (826 Ϯ 24 sec; n ϭ 5) was statistically significantly different from that at GluR3 o (590 Ϯ 82 sec; n ϭ 5), and (R,S)-BrHIBO showed a significantly slower 10 -90% rise time than that observed with 10 mM L-glutamate (343 Ϯ 39 sec for the 10 fastest patches of GluR1 o ). This difference in rise time could be because 1 mM BrHIBO is not a saturating concentration of agonist, whereas 10 mM L-glutamate represents ϳ20-fold EC 50 (Dingledine et al., 1999) .
To localize the region or regions of GluR1 o and GluR3 o responsible for determining , chimeric (Ch) GluR1 o -GluR3 o receptors were created, and their desensitization properties were measured (Figs. 1, 3 ). All of the tested receptors were functionally expressed in oocytes and showed almost complete desensitization to 10 mM L-glutamate (Table 1) . Chimeras 6 and 7 had values that were not statistically significantly different from one another but that were, however, intermediate between the values for GluR1 o and GluR3 o . This suggested that there was an amino acid residue or residues in both the N-and C-terminal halves of the S2 region that was responsible for determining .
Desensitization of AMPAR point mutants
Alignment of the S2 regions of GluR1 o and GluR3 o (Fig. 4 A) reveals 15 amino acid differences. Therefore, all these residues in GluR1 o were individually changed to the corresponding GluR3 o residue, and was measured (Fig. 4 B, Table 1 ). All mutants were functional when expressed in oocytes. For three mutants (Y714F, Y716F, and R757G), a decreased was observed compared with GluR1 o but full conversion to the rapid GluR3 o desensitization rate was not obtained. Residue R757 of GluR1 o corresponds to the R/G editing site and is known to affect desensitization, as well as the recovery from desensitization, after brief application of agonist to AMPARs (Lomeli et al., 1994) . Because R757 is located within the C-terminal half of the S2 region (Ch6) and Y714 and Y716 are contained within the N-terminal half (Ch7), this explains why each chimera only showed a partial effect on . It was decided to construct multiple-point mutations of these residues to obtain a full conversion of GluR1 o to that of GluR3 o .
Desensitization, recovery, and deactivation of AMPAR mutants
For the double-point mutant (Y714F, Y716F)GluR1 o , was statistically significantly different from that for GluR1 o and for GluR3 o (Fig. 4 B, Table 1 ). The double-point mutant (Y714F, R757G)GluR1 o had a value that was intermediate between GluR1 o and GluR3 o and was statistically significantly different from the single-point mutant (Y714F)GluR1 o but not different from (R757G)GluR1 o , displaying a lack of additivity of effect on for these two amino acid residues. Yet, creation of the doublepoint mutant (Y716F, R757G)GluR1 o completely converted the desensitization rate constant to a value that was not different from GluR3 o . The effects of the double mutations in this case are synergistic, because each of the single-point mutations only partially changed the value toward that of GluR3 o . The triple-point mutant (Y714F, Y716F, R757G)GluR1 o was also evaluated and found not to be statistically different from GluR3 o or from (Y716F, R757G)GluR1 o , indicating that the effects of Y714F and Y716F exchange are not additive. Therefore, the two key amino acid residues that seem to be responsible for controlling in GluR1 o are R757 and Y716, although Y714 may have some small effect as well. It was of interest to see whether the complementary changes in GluR3 o could result in a slower desensitization rate, as seen for GluR1 o . However, the mutants (F728Y)GluR3 o and (F728Y, G769R)GluR3 o desensitized at rates that were not statistically significantly different from wild-type GluR3 o (Table 1) . Similar results were obtained with the homologous mutations in GluR4c o , which also contains a phenylalanine at this position.
To test whether these point mutations have any effect on the rate of recovery from desensitization, rec was measured for wild-type GluR1 o and GluR3 o as well as for several GluR1 o mutants (Fig. 5, Table 1 ). Four mutants [(Y714F, Y716F, R757G)GluR1 o , (Y714F, R757G)GluR1 o , (Y716F, R757G)GluR1 o , and (R757G)GluR1 o ] exhibited a faster recovery from desensitization than did wild type, whereas (Y714F, Y716F)GluR1 o and (Y716F)GluR1 o were indistinguishable from GluR1 o . The data suggest that this rec effect occurs because of the R/G site (Lomeli et al., 1994) and that the values are in the same range as reported previously for GluR1 o (147 msec) (Partin et al., 1996) . This implies that Y714 or Y716 are not involved in recovery from desensitization. Interestingly, GluR3 o had a rec that was not different from GluR1 o , suggesting that residues in GluR3 o other than the R/G site may be involved in controlling rec . These mutants and wild-type receptors were also evaluated with respect to their deactivation rate ( deact ) after a brief (1 msec) application of 10 mM L-glutamate (Fig. 5, Table 1 ). The deact value obtained here for GluR1 o is similar to that reported previously (1.1 Ϯ 0.2 msec, Mosbacher et al., 1994 ; 0.80 Ϯ 0.04 msec, Partin et al., 1996) , and none of these mutants differed significantly from wild-type. 
AMPAR pharmacology
These Y/F and R/G exchanges were then evaluated with regard to effects on agonist potency (EC 50 ) and affinity (K i ). For the latter experiments, the mutants (Y716F, R757G)GluR1 o , (Y716F)GluR1 o , (F728Y, G769R)GluR3 o , and (F728Y)GluR3 o were engineered into recombinant baculoviruses and expressed by infection in Sf9 cells. Receptor expression was verified by SDS-PAGE and Western immunoblotting as described previously (Nielsen et al., 1998) , and all mutants had the same M r as the respective wild-type receptor (data not shown). Whereas agonists such as AMPA, KA, and L-glutamate have little or no selectivity between GluR1 o and GluR3 o (Banke et al., 1997) , (R,S)-BrHIBO exhibits an ϳ28-fold selectivity for GluR1 o (EC 50 ϭ 7.2 Ϯ 2.8 M; n ϭ 5) over GluR3 o (EC 50 ϭ 198 Ϯ 31 M; n ϭ 5) (Fig. 6 A, Table 2 ). Interestingly, at the mutants (Y716F, R757G)GluR1 o , (Y714F,Y716F, R757G)GluR1 o , and (Y716F)GluR1 o , (R,S)-BrHIBO had a potency that was not statistically significantly different from that at GluR3 o . Similarly, at the mutants (F728Y, G769R)GluR3 o and (F728Y)GluR3 o , (R,S)-BrHIBO had a potency that was not different from GluR1 o . These results imply that the R/G site is not involved in this change in potency. Hence, the agonist potency for (R,S)-BrHIBO at GluR1 o and GluR3 o was interchanged by the Y716/ F728 point exchanges. In comparison, the potency of (R,S)-BrHIBO at (Y714F, R757G)GluR1 o was unchanged from wildtype GluR1 o (Table 2) , also indicating that neither residue Y714 nor residue R757 are important for this switch in agonist potency.
In binding experiments made on Sf9 cell membranes expressing wild-type AM PARs, the compounds L-glutamate, L-quisqualate, AMPA, and KA exhibited little subtype selectivity (Table 2 ). In contrast, (R,S)-BrHIBO showed a 69-fold selectivity for GluR1 o (K i ϭ 173 Ϯ 37 nM) over GluR3 o (K i ϭ 12.0 Ϯ 2.4 M) (Fig. 6 B, Table 2 ), which is in agreement with the higher potency of (R,S)-BrHIBO seen at GluR1 o . (R,S)-BrHIBO had an affinity for the mutant (F728Y, G769R)GluR3 o that was not different from that at GluR1 o but was different from GluR3 o . The affinity of (R,S)-BrHIBO at the mutant (Y716F, R757G)GluR1 o was different from that at both GluR3 o and GluR1 o but is clearly approaching the lower affinity seen at GluR3 o . Therefore, these complementary mutations have effectively reversed the pharmacology of (R,S)-BrHIBO at GluR1 o and GluR3 o . Yet there was no major change in the L-glutamate affinity at these mutants compared with the wild-type receptors. (R,S)-AMPA showed only a threefold lower affinity at (Y716F, R757G)GluR1 o compared with GluR1 o and no change in affinity at (F728Y, G769R)GluR3 o compared with GluR3 o . Because the R/G site is expected to be localized far away from the binding pocket in GluR1 o and GluR3 o , as it is in GluR2 (Armstrong et al., 1998; Armstrong and Gouaux, 2000) , the observed changes in binding affinity could most probably be attributed to the Y/ F site. This was verified by subsequent measurement of the affinity of (R ,S)-BrHI BO at the mutant (Y716F)GluR1 o , which was not different from (Y716F, R757G)GluR1 o , and the mutant (F728Y)GluR3 o , which was not different from (F728Y, G769R)GluR3 o ( Table 2 ). In contrast to BrHI BO, Y/ F exchange had the opposite effect on the binding affinity of K A, causing a sevenfold decrease for GluR3 o and a 14-fold increase for GluR1 o . This suggests that BrHI BO interacts very differently with these residues than does K A.
Not unexpectedly, it was found that GluR2 o (R) also binds (R,S)-BrHIBO with an affinity that is about the same as that of GluR1 o (Coquelle et al., 2000) , because GluR2 has a tyrosine in the position homologous to Y716 of GluR1 o . It is predicted that GluR4 o should have a low affinity for these analogs, similar to GluR3 o , because a phenylalanine residue is present at this position in GluR4 o . Furthermore, this similarity in GluR1/GluR2 sensitivity to BrHIBO suggests that use of the GluR2-S1S2 binding site model may provide relevant information about the GluR1 binding site.
Molecular modeling of GluR1 and GluR3 binding sites
To improve our understanding of the reasons for these differences in binding and desensitization between GluR1 o and GluR3 o , homology models of the ligand binding domains of GluR1 o , GluR3 o , and GluR4 o were generated using the x-ray crystal structures of GluR2-S1S2 constructs (Armstrong et al., 1998; Armstrong and Gouaux, 2000) . Seven amino acids residues interact directly with the ligand within the GluR2-S1S2 constructs: Y450, P478, T480, and R485 from S1, and S654, T655, and E705 from S2. These correspond to the homologous residues Y464, P492, T494, R499, S668, T669, and E719 in GluR1 (numbering from the initiation methionine) or with Y474, P502, T504, R509, S680, T681 and E731 in GluR3. As expected from the high amino acid sequence identity of these proteins within the binding site, all seven of the identified ligand-binding residues in GluR2-S1S2 are predicted to occupy virtually the same spatial positions in GluR1 and GluR3. The question arises as to why AMPA has the same affinity for both GluR1 o and GluR3 o while homoibotenic acid analogues such as BrHIBO and MeHIBO exhibit subtype selectivity (Coquelle et al., 2000) . To investigate this question, L-glutamate, AMPA, and BrHIBO were docked into the binding sites of the models of GluR1 and GluR3 (Fig. 7) . Docking was guided by the experimentally observed binding modes of AMPA and glutamate to GluR2-S1S2J (Armstrong and Gouaux, 2000) . The crystal structures of the GluR2-S1S2 constructs show that a number of water molecules are present within the binding site and that, to some extent, their positions depend on the nature of the bound ligand. On the basis of the very high degree of homology, it is most probable that the water matrix observed within GluR2-S1S2 for a given ligand is also present in GluR1 and GluR3. This hypothesis was confirmed by GRID analysis. On this basis, water structure was added to the models within a radius of 8.5 Å of the ligand. The water molecules W1-W3 are of most importance in the present context. In the case of the docking of BrHIBO (for which no GluR2-S1S2 crystal structure has yet been published), it was necessary to relocate W2. Note that for both BrHIBO and AMPA to interact with the same amino acid residues within GluR2-S1S2, the heterocyclic rings of BrHIBO and AMPA must adopt different orientations. In particular, the negatively charged oxygens (labeled O1 in Fig. 7 ) of these two ligands must point in opposite directions (Christensen et al., 1992; Greenwood et al., 1998) . The O2 of BrHIBO overlaps closely with the position of W2 in the AMPA complex, but by preserving the position of W2 relative to the flipped isoxazole ring of BrHIBO, this water molecule comes to occupy a zone close to that of W2 in the glutamate structure. This is confirmed to be a favorable site for water by GRID analysis. Because hydrogen atoms are undetectable by protein crystallography, and therefore not included in the experimental GluR2-S1S2 structures, their positions must be determined by calculation. Where necessary, Monte Carlo simulations were used to resolve ambiguities in assigning the pattern of H bonding. The positions of selected protons and the alignment of their H bonds are indicated in Figure 7 .
DISCUSSION
Receptor desensitization
Agonist binding can cause iGluRs to either open or desensitize (assume a closed state). However, little is known about how agonist binding is coupled to channel gating. Here, we took advantage of the known differences in desensitization properties of the AMPAR subunits (Lomeli et al., 1994; Banke et al., 1997; Stern-Bach et al., 1998) for an investigation of the underlying molecular mechanism or mechanisms involved in GluR1 o desensitization. GluR1 o was chosen as an example of an AMPAR Figure 5 . Deactivation and recovery from desensitization. A, Recovery from desensitization in an outside-out patch expressing wild-type GluR1 o receptors. L-glutamate (10 mM) was applied for 1 msec at the following time intervals (in msec) : 0, 50, 100, 150, 200, 250, 300, 350, 400, 500, 600, and 800. rec subunit exhibiting a slow desensitization rate and GluR3 o as an example of one having a fast rate. Evaluation of a series of chimeric receptors focused on exchange of amino acid sequences in the S2 region of GluR1 o because previous evidence had suggested that amino acids in the S2 region were important for GluR1 o desensitization properties (Mano et al., 1996; Banke et al., 1997) . The single-point GluR1 o mutations Y714F and Y716F each created receptors having a faster than wild type, and point exchanges at other residues in S2 that differ between GluR1 o and GluR3 o had no effect on , except when GluR1 o or GluR3 o were exchanged at the R/G site, which had been identified previously as being important for controlling AMPAR desensitization properties (Lomeli et al., 1994) . However, only a double exchange of Y716F plus R757G in GluR1 o converted the desensitization rate to that seen with GluR3 o . Therefore, we have identified that residue Y716 also somehow plays a very important role in the desensitization mechanism of GluR1 o and that neighboring Y714 can weakly interact with this process also, but cannot completely substitute for Y716. Remarkably, the complementary mutations in GluR3 o did not result in an increase in toward that of GluR1 o ; rather, there was little effect on . Our interpretation of these results is that the desensitization mechanism or mechanisms of the AMPAR subunits may not be entirely the same, at least with respect to the subunit amino acid residues that are involved. It is likely that other amino acid residues in the S1 region, or perhaps even residues N-terminal to S1, are involved in the desensitization mechanism. Our own data with chimera 2 and other mutagenesis studies (Uchino et al., 1992; Mano et al., 1996; Stern-Bach et al., 1998 ) support this interpretation.
Residues Y714 and Y716 are not involved in recovery from desensitization or deactivation but seem to be specifically involved in controlling the rate of GluR1 o desensitization. The deactivation rate constant ( deact ) for L-glutamate at GluR1 o measured in this study is in good agreement with the values given in the literature Partin et al., 1996) . However, no changes in deact were observed with the mutant GluR1 o receptors. In contrast, all of the multiple-point GluR1 o mutants containing the exchange R757G exhibited faster recovery times than wild-type GluR1 o , whereas neither the double exchange of Y714F plus Y716F nor the Y716F single exchange altered rec . This is consistent with the finding that the R/G site controls recovery from desensitization in GluR1 o .
Binding site interactions
In addition to effects on the time course of receptor desensitization and deactivation, it was a possibility that the Y/F exchange in GluR1 o was somehow directly affecting agonist binding. Previous studies have shown that the S1 region and the N-terminal portion of the S2 region are involved in ligand binding (Uchino et al., 1992; Stern-Bach et al., 1994; Li et al., 1995; Mano et al., 1996) . Subsequently, the x-ray crystal structures were solved for both the ligand-bound and unbound (apo) versions of soluble GluR2-S1S2 binding site constructs (Armstrong et al., 1998; Armstrong and Gouaux, 2000) . This indicated that the C-terminal region of S2, which includes the flip/flop region as well as the R/G site, is located far away from the binding pocket, on the solvent-exposed surface of the protein. In contrast, residue Y716 lies in the N-terminal part of the S2 region of GluR1 o , within the binding pocket. So, could an exchange of binding site properties between GluR1 o and GluR3 o be seen on Y/F exchange?
Whereas most agonists at AMPARs show little or no subtype selectivity, (R,S)-BrHIBO exhibited a 28-fold preference for GluR1 o compared with GluR3 o in terms of potency (EC 50 ) and a 69-fold preference in terms of affinity (K i ). The fact that both BrHIBO potency and affinity could be transposed by the Y/F exchange between GluR1 o and GluR3 o leads to the conclusion that Y716 does interact in some manner with (R,S)-BrHIBO in the GluR1 o binding domain. Because no change in EC 50 , compared with wild type, was observed with the mutant (Y714F, R757G)GluR1 o , it is also concluded that the Y714 residue is not involved in agonist interactions. Therefore, Y716 seems to play a key role in determining both the slower desensitization rate of GluR1 o and the higher affinity of a subtype-selective agonist. Figure 6 . Pharmacology of mutant and wild-type AMPARs. Potency (EC 50 ) and affinity (K i ) of (R,S)-BrHIBO at wild-type and mutant AMPARs are shown. A, Receptors were expressed in X. laevis oocytes, and steady-state currents were measured after application of increasing concentrations of (R,S)-BrHIBO. EC 50 was determined by fitting data to a logistic equation as described in Materials and Methods. Curves are mean Ϯ SEM from 5 to 16 oocytes. B, Receptors were expressed in Sf9 cell membranes and drug affinity was measured by (R,S)-[ 3 H]AMPA competition binding assays. K i was determined by nonlinear, iterative fitting of the data as described in Materials and Methods. Shown are the mean Ϯ SD of triplicate determinations from single experiments (replicated 3-6 times). E, GluR1 o (EC 50 ϭ 7.2 Ϯ 2.8 M; n ϭ 5; K i ϭ 183 nM); F, GluR3 o (EC 50 ϭ 198 Ϯ 31 M; n ϭ 5; K i ϭ 9.53 M); ‚, (Y716F)GluR1 o (EC 50 ϭ 200 Ϯ 27 M; n ϭ 16; K i ϭ 3.69 M); OE, (F728Y)GluR3 o (EC 50 ϭ 2.6 Ϯ 0.4 M; n ϭ 5; K i ϭ 423 nM).
1.36 to convert kilocalories per mole to log units at 298°K, the net result is a prediction that the ratio between the selectivities of MeHIBO and AMPA at GluR1 versus GluR3 will be 16:1. Given that AMPA is roughly equipotent at both receptors, MeHIBO is predicted to bind 16 times more weakly at GluR3 o than GluR1 o . This finding is in excellent agreement with the experimentally observed binding affinities of MeHIBO (K i ϭ 471 Ϯ 134 nM at GluR1 o and 7270 Ϯ 2200 nM at GluR3 o ) (Coquelle et al., 2000) . Therefore, we conclude that the observed binding selectivity of the HIBO derivatives for GluR1 over GluR3 resides primarily in the effect of the Y/F position on the hydrogen-bonding network linking the ligand with W3 to Y716 in GluR1. Neither glutamate nor AMPA show this susceptibility because of the weaker links between W3 and the ligand and, in the latter case, because of a ( D-F) . The seven amino acid residues that have been shown to interact directly with ligands in the GluR2-S1S2 constructs correspond to the homologous residues Y464, P492, T494, R499, S668, T669, and E719 in GluR1 o (numbering from the initiation methionine) or with Y474, P502, T504, R509, S680, T681, and E731 in GluR3 o . Residues are numbered (in A and D), with the homologous GluR2 residue (Armstrong et al., 1998) rather weak connection involving W2, for which only a small decrease in affinity is observed.
Finally, because the water molecule W3 connects Y716 in GluR1 o (Fig. 7A-C ) with the T700 -E416 H bond, it is also probable that the water structure and H-bond matrix, along with the altered volume occupied by tyrosine versus phenylalanine, influence the desensitization properties of the receptor, as observed here in the case of L-glutamate. Further refinements of our models, including quantum mechanical calculations of the bond energy of the T700 -E416 H bond, are underway and should shed more light on the role of this region in controlling desensitization as well as binding.
